Clinical Trial Update: A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for anlotinib and AK105 injection in advanced head, neck, and chest cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chest Cancer
• Head and Neck Cancer

Drugs mentioned

• AK105 (anti-PD-1 monoclonal antibody)
• Anlotinib (anlotinib)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Advanced Head, Neck and Chest Cancer | Phase 2 | Status: UNKNOWN